Assessment of Dexmedetomidine's Hemodynamic Impact in General Anesthesia for Outpatient Surgical Procedures

The primary objective of this study is to evaluate the **hemodynamic effect** of **dexmedetomidine** when used as a general anesthetic in scheduled outpatient surgery. This is clinically relevant as understanding the hemodynamic profile of dexmedetomidine can inform anesthesiologists about its safety and efficacy, potentially improving patient outcomes during outpatient procedures.

The clinical trial involves participants undergoing **general anaesthetic** for outpatient surgery. The study population includes both male and female subjects, with an age range spanning from 18 to 64 years. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet, physical activity, or habits. The selection criteria for the trial population have not been disclosed, and no principal inclusion criteria have been specified. The trial aims to gather data from a diverse group of adults within the specified age range, ensuring a broad representation of the general population undergoing outpatient surgical procedures.

The clinical trial is designed to evaluate the **hemodynamic** effects of dexmedetomidine in patients undergoing scheduled outpatient surgery under general anesthesia. The trial is structured as a randomized, double-blind, controlled study, ensuring that neither the participants nor the researchers know which treatment the participants are receiving, thus minimizing bias. The trial is expected to commence recruitment on October 19, 2023, and is projected to conclude by December 31, 2026, providing a comprehensive assessment over a significant period.

Participants will undergo a series of study visits, beginning with an inclusion visit, which serves as a screening to determine eligibility based on predefined criteria. This visit will involve a thorough review of the participant's medical history and baseline assessments. Following the inclusion visit, participants will attend scheduled follow-up visits, where ongoing assessments and monitoring will be conducted to evaluate the effects of the intervention. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The trial will culminate in an end-of-study visit, where final evaluations will be performed, and participants will be debriefed on the study's completion.

The expected duration of participant involvement will vary depending on the individual's enrollment date but will generally span the entire trial period. Participants may be subject to early termination from the study if they experience adverse effects, fail to comply with study protocols, or withdraw consent. The trial's design and procedures are meticulously crafted to ensure the collection of reliable and valid data, contributing to the understanding of dexmedetomidine's hemodynamic effects in the specified surgical context.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of these details limits the ability to describe the treatment regimen comprehensively.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized under Phase 5, indicating a focus on post-marketing surveillance and long-term effects. The estimated recruitment start date is October 19, 2023, with an anticipated end date of December 31, 2026. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, the trial will likely involve systematic data collection and analysis to evaluate treatment outcomes. The methods and schedule for measuring efficacy will be aligned with standard clinical trial practices, ensuring rigorous assessment of the intervention's impact. The trial's design will adhere to established protocols to ensure the reliability and validity of the efficacy data collected throughout the study period.